Publication | Open Access

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cobimetinib Versus RegorafenibOncologyMedicinePathologyColorectal CancerMetastatic Colorectal CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyPhase 3